Regeneron’s COVID-19 antibody drug can now be administered subcutaneously

Shares of Regeneron Pharmaceuticals Inc. were up 1.0% in premarket trading on Friday after the company said U.S. regulators had authorized a lower-dose and subcutaneous version of its COVID-19 antibody treatment. The updated emergency-use authorization now says that patients will receive a dose that is half the size of the original dose of the monoclonal antibody. In addition, providers can administer the drug using a subcutaneous injection instead of intravenous infusion when needed. Regeneron’s antibody cocktail can be prescribed to people who are at least 12 years, have received a positive COVID-19 test, and have mild or moderate cases of COVID-19. The company also said it expects to get full approval for the antibody therapy from the Food and Drug Administration later this summer. Regeneron’s stock is up 4.6% so far this year, while the broader S&P 500 has gained 11.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.